Protagonist Therapeutics Inc
Research Protagonist Therapeutics Inc (PTGX) on Bullrun: valuation model: 64.2% overvalued, market cap USD 9.37B, P/E 139.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPTGX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal64.2% overvalued
- Market capUSD 9.37B
- P/E139.7
- Financial periodQ2 2026
- RevenueUSD 213.48M
- Net incomeUSD 162.85M
- Free cash flowUSD 218.88M
Valuation Snapshot
Bullrun's latest valuation model marks Protagonist Therapeutics Inc as 64.2% overvalued; latest market cap is USD 9.37B; P/E is 139.7.
Peer valuation comparison
Latest P/E is 139.71x versus a Healthcare sector median of 24.6x (467.9% above).
Latest P/E is 139.71x versus a United States median of 23.85x (485.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 46.02M | -USD 130.15M | USD 56.08M | n/a | -2.05 | USD 128.39M | USD 10.32M | USD 614.71M |
| FY2024 | USD 434.43M | USD 275.19M | USD 182.80M | n/a | 4.23 | USD 97.25M | USD 10.87M | USD 675.30M |
| FY2023 | USD 60.00M | -USD 78.96M | -USD 70.85M | n/a | -1.39 | USD 186.73M | USD 1.14M | USD 336.68M |
| FY2022 | USD 26.58M | -USD 127.39M | -USD 108.93M | n/a | -2.6 | USD 125.74M | USD 3.66M | USD 215.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 9.37B | 139.7 | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.47B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.36B | 9.2 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.32B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 536.75M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.64B | n/a | n/a | n/a |
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
ETFs that hold Protagonist Therapeutics Inc
Protagonist Therapeutics Inc is one of the ten largest holdings of 4 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| iShares S&P SmallCap 600 UCITS ETF USD (Dist) | 0.53% | 0.30% |
| Xtrackers Russell 2000 UCITS ETF 1C | 0.29% | 0.30% |
| iShares Ageing Population UCITS ETF USD (Acc) | 0.65% | 0.40% |
| Vanguard Russell 2000 U.S. Small-Cap UCITS ETF USD Acc | 0.29% | 0.20% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Protagonist Therapeutics Inc overvalued or undervalued?
Bullrun's valuation model currently marks Protagonist Therapeutics Inc as 64.2% overvalued.
What is Protagonist Therapeutics Inc's market cap?
Protagonist Therapeutics Inc's market capitalization is USD 9.37B.
What is Protagonist Therapeutics Inc's P/E ratio?
Protagonist Therapeutics Inc's price-to-earnings (P/E) ratio is 139.7.
What does Protagonist Therapeutics Inc do?
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.